Relmada Therapeutics Inc. (RLMD) — NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearanceLong-term extension NDV-01 Phase 2 data demonstrate continued durability of response: 86% of 12-month complete responders remained in complete response at 18 months, with no Grade ≥3 treatment-related adverse events or discontinuationsRegistrational Phase 3 program renamed SPECTRUM; two independent registrational pathways in NMIBC remain unchangedCash,
Source: GlobeNewswire — read the full announcement there.
See our Relmada Therapeutics company profile for background, links, and more Relmada Therapeutics news.